Cambridge Investment Research Advisors
AGL icon

Cambridge Investment Research Advisors’s Agilon Health AGL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,255
Closed -$32K – 3813
2025
Q3 		$32K Sell
1,255
-3
-0.2% -$113 ﹤0.01% 3674
2025
Q2 		$72K Hold
1,258
– – ﹤0.01% 3507
2025
Q1 		$136K Sell
1,258
-7
-0.6% -$609 ﹤0.01% 3297
2024
Q4 		$60K Hold
1,265
– – ﹤0.01% 3364
2024
Q3 		$124K Sell
1,265
-194
-13% -$25.1K ﹤0.01% 3234
2024
Q2 		$239K Buy
1,459
+182
+14% +$25.9K ﹤0.01% 2885
2024
Q1 		$195K Buy
1,277
+5
+0.4% +$832 ﹤0.01% 3030
2023
Q4 		$399K Buy
1,272
+4
+0.3% +$1.45K ﹤0.01% 2375
2023
Q3 		$563K Sell
1,268
-1
-0.1% -$452 ﹤0.01% 1991
2023
Q2 		$550K Buy
1,269
+46
+4% +$25.9K ﹤0.01% 2055
2023
Q1 		$726K Sell
1,223
-48
-4% -$26.9K ﹤0.01% 1795
2022
Q4 		$513K Buy
1,271
+8
+0.6% +$3.75K ﹤0.01% 1992
2022
Q3 		$740K Sell
1,263
-196
-13% -$117K ﹤0.01% 1680
2022
Q2 		$796K Buy
1,459
+22
+2% +$11.1K ﹤0.01% 1633
2022
Q1 		$910K Hold
1,437
– – ﹤0.01% 1641
2021
Q4 		$970K Buy
+1,437
New +$874K ﹤0.01% 1600

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Cambridge Investment Research Advisors's AGL Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of Agilon Health (AGL) in Q4 2025, closing a stake of 1,255 shares — an estimated $32K sold.

Cambridge Investment Research Advisors first reported a position in AGL in Q4 2021 and held it in 16 quarters. The position peaked at $970K in Q4 2021. 194 funds tracked by Wall St. Rank hold AGL as of Q4 2025.

  • Cambridge Investment Research Advisors reported no remaining Agilon Health position as of Q4 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,255 Agilon Health shares in Q4 2025, an estimated $32K.
  • Cambridge Investment Research Advisors first reported a position in Agilon Health in Q4 2021 and held it in 16 quarters.
  • Cambridge Investment Research Advisors's Agilon Health position peaked at $970K in Q4 2021.
  • 194 funds tracked by Wall St. Rank held Agilon Health as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.